clinical trial · NCT04929223
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche·phase1·recruiting·n = 542
Metastatic Colorectal CancerInavolisibBevacizumabCetuximabAtezolizumabTiragolumabSY-5609DivarasibFOLFOX
brief summary
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
started
Oct 22, 2021
primary completion
Aug 31, 2030
completion
Aug 31, 2030
last updated
Mar 31, 2026
official title
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol